Unknown

Dataset Information

0

Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.


ABSTRACT: The 18 kDa translocator protein (TSPO) is a target for development of diagnostic imaging agents for glioblastoma and neuroinflammation. Clinical translation of TSPO imaging agents has been hindered by the presence of a polymorphism, rs6971, which causes a non-conservative substitution of alanine for threonine at amino acid residue 147 (TSPO A147T). Disclosed brain-permeant second-generation TSPO ligands bind TSPO A147T with reduced affinity compared to the wild type protein (TSPO WT). Efforts to develop a TSPO ligand that binds TSPO WT and TSPO A147T with similarly high affinity have been hampered by a lack of knowledge about how ligand structure differentially influences interaction with the two forms of TSPO. To gain insight, we have established human embryonic kidney cell lines stably over-expressing human TSPO WT and TSPO A147T, and tested how modifications of a novel N-alkylated carbazole scaffold influence affinity to both TSPO isoforms. Most of the new analogues developed in this study showed high affinity to TSPO WT and a 5-6-fold lower affinity to TSPO A147T. Addition of electron-withdrawing substituents yielded analogues with highest affinity for TSPO A147T without decreasing affinity for TSPO WT. This knowledge can be used to inform further development of non-discriminating TSPO ligands for use as diagnostic markers for glioblastoma and neuroinflammation irrespective of rs6971.

SUBMITTER: Sokias R 

PROVIDER: S-EPMC6071920 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination.

Sokias Renee R   Werry Eryn L EL   Chua Sook W SW   Reekie Tristan A TA   Munoz Lenka L   Wong Erick C N ECN   Ittner Lars M LM   Kassiou Michael M  

MedChemComm 20161115 1


The 18 kDa translocator protein (TSPO) is a target for development of diagnostic imaging agents for glioblastoma and neuroinflammation. Clinical translation of TSPO imaging agents has been hindered by the presence of a polymorphism, rs6971, which causes a non-conservative substitution of alanine for threonine at amino acid residue 147 (TSPO A147T). Disclosed brain-permeant second-generation TSPO ligands bind TSPO A147T with reduced affinity compared to the wild type protein (TSPO WT). Efforts to  ...[more]

Similar Datasets

| S-EPMC3820042 | biostudies-literature
| S-EPMC9085532 | biostudies-literature
| S-EPMC8292990 | biostudies-literature
| S-EPMC8440208 | biostudies-literature
| S-EPMC4210126 | biostudies-literature
| S-EPMC4399280 | biostudies-literature
| S-EPMC7171652 | biostudies-literature
| S-EPMC4567528 | biostudies-literature
| S-EPMC8712295 | biostudies-literature
| S-EPMC4393609 | biostudies-other